12 / 12
Page 26
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 3
Breast Cancer
November 01-02, 2017 | Toronto, Canada
7
th
World Congress on
Medicinal plants in breast cancer therapy
Tagne Simo Richard
1
, Armel Herve Nwabo Kamdje
1
, Mbo Amvene Jeremie
1
, Takam Kamga Paul
2
and
Farah Mukhtar
3
1
University of Ngaoundere, Cameroon
2
University of Karachi, Pakistan
3
University of Verona, Italy
V
arious active compounds (or their semi-synthetic
derivatives) derived from medicinal plants have been
assessed for their efficacy and tolerability in the treatment
of breast cancer. Some of these plant species, including
Taxus baccata
(paclitaxel, docetaxel),
Podophyllum peltatum
(etoposide),
Camptotheca acuminata
(camptothecin) and
Vinca rosea
(vinblastine, vinorelbine) have well recognized
antitumor activity in breast cancer, and have been evaluated
in clinical trials. For example, results from recent phase II/
III trials have established docetaxel as the most active single
agent in the treatment (first or second-line) of advanced
metastatic breast cancer. The treatment of breast cancer,
the most common malignancy among women worldwide,
remains puzzling partly due to the resistance to therapeutics,
which associates with the heterogeneity of case clinical
presentations, and limits in the current understanding of
the pathogenesis of solid cancers. Oxidative stress is closely
related to various diseases, including cancer. The human
body is exposed to free radicals, which cause oxidative
stress. Oxidative stress may lead to gene mutations leading
to carcinogenesis. Antioxidants are protector of the body,
preventing oxidative stress, by stabilizing free radicals.
Plants are good and cheap sources for the prevention and
treatment of oxidative stress and cancer. Major drawbacks
to antioxidant from plants based therapy and use in breast
cancer will be shown during presentation.
Speaker Biography
Armel Herve NWABO KAMDJE is currently a Senior Lecturer/Assistant Professor at the
Department of Biomedical Sciences of the University of Ngaoundere-Cameroon and
the editor in chief of the Journal of Diseases and Medicinal Plants. He has a MSc in
Biochemistry (University of Yaounde I-Cameroun) and a Ph.D in Human Oncological
Pathology and Stem Cell Biology and Clinical Application (University of Verona, Italy).
He currently works on the following topics: Cancer, Leukemia, Stem Cells, HIV, Signaling
pathways, Epigenetics, Breast Cancer, Macrophages, Neural Stem Cells, Autism, FASD
and Medicinal Plants.
e:
kamdjewa@yahoo.fr